Clair Daniel G, Beach Jocelyn M
Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH, USA.
Expert Rev Cardiovasc Ther. 2015 May;13(5):551-63. doi: 10.1586/14779072.2015.1036741.
Treatment of severe aortoiliac disease has dramatically evolved from a dependence on open aortobifemoral grafting to hybrid and endovascular only approaches. Open surgery has been the gold standard treatment of severe aortoiliac disease with excellent patency rates, but with increased length of stay and major complications. In contrast, endovascular interventions can successfully treat almost any lesion with decreased risk, compared to open surgery. Although primary patency rates remain inferior, secondary endovascular interventions are often minor procedures resulting in comparable long-term outcomes. The risks of renal insufficiency, embolization and access complications are not insignificant; however, most can be prevented or managed without significant clinical consequence. Endovascular therapies should be considered a first-line treatment option for all patients with aortoiliac disease, especially those with high-risk cardiovascular comorbidities.
重度主-髂动脉疾病的治疗已从单纯依赖开放性主动脉双股动脉搭桥术显著发展为采用杂交手术和仅进行血管腔内治疗的方法。开放性手术一直是重度主-髂动脉疾病的金标准治疗方法,通畅率极佳,但住院时间延长且有较多严重并发症。相比之下,与开放性手术相比,血管腔内介入治疗能以较低风险成功治疗几乎任何病变。虽然初次通畅率仍然较低,但二次血管腔内介入治疗通常是小手术,可产生相当的长期疗效。肾功能不全、栓塞和穿刺部位并发症的风险并非微不足道;然而,大多数情况下这些风险可以预防或处理,不会产生重大临床后果。血管腔内治疗应被视为所有主-髂动脉疾病患者的一线治疗选择,尤其是那些伴有高风险心血管合并症的患者。